Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
LENZ
vs
S&P 500
LENZ
S&P 500
Over the past 12 months, LENZ has underperformed S&P 500, delivering a return of -92% compared to S&P 500's +15% growth.
Stocks Performance
LENZ vs S&P 500
Performance Gap
LENZ vs S&P 500
Performance By Year
LENZ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
LENZ Therapeutics Inc
Glance View
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 152 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.